[Federal Register Volume 61, Number 160 (Friday, August 16, 1996)]
[Notices]
[Pages 42639-42640]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-20943]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
The inventions listed below are owned by agencies of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for U.S. companies and may also be available for licensing.
ADDRESS: Licensing information and copies of the U.S. patent
applications listed below may be obtained by contacting Allan Kiang,
J.D., at the Office of Technology Transfer, National Institutes of
Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-
3804; telephone: 301/496-7735 ext 270; fax: 301/402-0220. A signed
Confidential Disclosure Agreement will be required to receive copies of
the patent applications.
Immunization With Synthetic Peptides Generate Cytotoxic T Cell
Responses Against the EWS/FL1 1 Ewing's Sarcoma Fusion Protein and the
PAX-3/FKHR Alveolar Rhabdomysarcoma Fusion Protein
TJ Goletz, LJ Helman, JA Berzofsky (NCI), Filed 14 Sept 95, Serial No.
08/528,129
This invention provides novel methods of producing vaccines and
therapeutics to viral infections or cancer(s). This method utilizes
irradiated, peptide-pulsed antigen presenting cells (APCs) which are
coated with synthetic or recombinant peptides. These APCs can be used
to induce a tumor specific cytotoxic T lymphocyte (CTL) response. This
broadly applicable method uses safe, non-toxic synthetic or recombinant
peptides and does not utilize harmful adjuvants or live viral vectors.
Peptides derived from viral or bacterial antigens or mutant oncogene or
tumor suppressor gene products may be applied towards this method. For
example, using this method, a synthetic peptide which corresponds to
the site of the mutation in the tumor suppressor gene product p53 can
be used to induce a CTL response which kills tumor cells endogenously
expressing the mutant p53 gene. (portfolio: Cancer--Therapeutics,
biological response modifiers; Cancer--Therapeutics, vaccines)
O-Malonlytyrosyl Compounds, O-Malonllytyrosyl Compound-Containing
Peptides, and Uses Thereof
TR Burke, B Ye, M Akamatsu, X Yan, HK Kole, PR Roller (NCI), Filed 31
Mar 95, Serial No. 08/414,520
Phosphotyrosyl residues in signalling proteins, which appear to act
as molecular switches in phosphotyrosyl-dependent cellular signal
transduction pathways, are potential targets for therapeutic agents.
The phosphotyrosol-dependent signal transduction pathway is composed of
three elements: the protein kinases which add phosphates to tyrosine
residues, the protein phosphatases which remove the phosphate, and the
interaction of other signaling proteins with proteins containing
phosphotyrosyl residues. This invention describes a phosphotyrosyl
mimetic 0-malonyltryosine (OMT) which uses a malonate moiety in place
of phosphate that can be derivatized and thus potentially made
permeable to cell membranes. Peptides containing OMT residues are
therefore potential therapeutic agents for disease states with altered
cellular signaling including cancer. (portfolio: Cancer--Therapeutics,
conventional chemotherapy, antimetabolites)
Assay for Sensitivity of Tumors to DNA-Platinating Chemotherapy
E Reed, M Dadholkar, F Bostick-Burton (NCI), Filed 07 Mar 95, Serial
No. 08/399,617
The invention provides a method for determining the sensitivity of
a tumor tissue to treatment with platinum-based chemotherapy. The
method is based on detecting high levels of the mRNA for ERCC1 which
includes exon VIII or concurrent expression of ERCC1 and XPAC mRNAs in
fresh tumor tissues. Studies show that this method clearly
distinguishes between platinum-sensitive and platinum-resistant tumors
(J. Clin. Invest. 94:703-708, 1994). (portfolio Cancer--Research
Reagents, DNA based)
Confirmationally Constrained Diacylglycerol Analogues
VE Marquez, J Lee, R Sharma, S Wang, GWA Milne, MC Nicklaus, PM
Blumberg, NE Lewin (NCI), Filed 13 Jan 95, Serial No. 08/372,602
Diacylglycerol (DAG) is a member of the second messenger system in
cell signal transduction. DAG is released from membrane phospholipids
in response to the binding of a variety of agonists. Once released, DAG
binds to the regulatory domain of protein kinase C (PK-C) and in doing
so aids in the activation of the kinase. PK-C, when activated, is
capable of phosphorlyating a variety of other proteins involved in
cellular processes including growth, differentiation, inflammation,
nerve function, tumor promotion, and ocogenic expression. Given the
global action of PK-C, molecules that can activate or inactivate this
enzyme would be very useful. The claims of this
[[Page 42640]]
invention describe a series of a diaclyglycerol analogues, which act as
potent pharmacological agonists of PK-C and can be easily synthesized.
(portfolio: Cancer--Therapeutics, conventional chemotherapy,
antimetabolites)
Treatment of Cancer With Human Chorionic Gonadotropin
Y Lunardi-Iskandar, RC Gallo, JL Bryant (NCI), Filed 5 Aug 94, Serial
No. 08/286,299
A major complication in treating tumors is that many of the known
treatments, such as surgery, radiation or chemotherapy, have serious
side effects. Other types of cancers are not amenable to conventional
therapies due to the fact that the exact mechanism by which the disease
develops is unknown. An example of this type of cancer is Kaposis
sarcoma. Kaposis sarcoma is the most common malignancy in AIDS
patients. Current therapies for Kaposis sarcoma can cause myelotoxicity
and neurotoxicity. In addition, these treatments can also induce
immunosuppression. This invention describes the use of a naturally
occurring human hormone, human chronic gonadotropin, for the treatment
of Kaposis sarcoma. Human chorionic gonadotropin may also be useful for
the treatment of breast, prostate, ovary, and stomach carcinomas, as
well as neuroblastomas. (portfolio: Infectious Diseases--Therapeutics,
anti-virals, AIDS; Cancer--Therapeutics, conventional chemotherapy,
hormonal compounds)
Therapeutic Polyamines
HS Basu, LJ Marton, BG Feuerstein, K Samejima (University of
California; Josai University; NCI), Filed 05 Nov. 93, Serial No. 08/
147,527
Most previous attempts to retard the growth of tumor cells by
depleting the intracellular polyamine pool have been directed at
inhibiting enzymes in the polyamine biosynthetic pathway; a process
that does not completely deplete endogenous stores of these molecules.
To date, most attempts at using polyamine biosynthetic inhibitors have
resulted in incomplete inhibition of cell growth. With this invention,
analogs have been developed that, while binding physically to DNA, do
not function like natural polyamines and indeed case almost complete
depletion of intracellular stores of these compounds. These compounds
have shown great promise in vitro and in vivo against various tumors.
Additionally, these synthetic polyamines have proven to be tumor
sensitizers in conjunction with other conventional chemotherapeutices
in vivo. (portfolio: Cancer--Therapeutics, conventional chemotherapy,
other)
Topoisomerase II Inhibitors And Therapeutic Uses Therefor
Y Pommier, T MacDonald, JS Madalengoitia (NCI), Filed 23 Oct 92, Serial
No. 07/965,922 CIP of 07/868,408)
DNA topology is maintained in all cells by the action of a class of
enzymes termed topoisomerases. Many drugs used in cancer chemotherapy
function by inhibiting the action of topoisomerases. This invention
embodies a compound, azatoxin, which is a inhibitor of both
topoisomerase II and tubulin polymerization. Azatoxin is unique
compared to other topoisomerase inhibitors in that it inhibits the
catalytic activity of the enzyme at specific sites of DNA. Certain
derivatives of azatoxin are capable of inhibiting either topoisomerase
activity or tubulin polymerization but not both. Therefore these
derivatives are expected to be especially potent therapeutic compounds.
(portfolio: Cancer--Therapeutics, conventional chemotherapy,
antimetabolites)
Dated: August 6, 1996.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 96-20943 Filed 8-15-96; 8:45 am]
BILLING CODE 4140-01-M
